Is NCT03135509 results overdue?

Yes — results are overdue. Primary completion was 2017-06-28; the FDAAA-801 reporting deadline (2018-06-28) passed 2915 days ago and no results are posted on ClinicalTrials.gov.

A Study to Assess the Relative Bioavailability of a New CC-220 Capsule Formulation, Compared to a Reference CC-220 Capsule Formulation, in Healthy Adult Subjects

NCT ID	NCT03135509 ↗
Sponsor	Celgene (INDUSTRY)
Phase	PHASE1
Status	COMPLETED
Primary completion	2017-06-28 (ACTUAL)
Reporting deadline	2018-06-28 (completion + 365d)
Days overdue	2915
Results posted	No — check results tab ↗
FDA-regulated	drug: yes, device: no
Provenance	Flagged overdue on 2026-06-21 · SHA-256 `44d42483382adc0f…` (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT03135509. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.